Ana Montes

1.4k total citations
31 papers, 236 citations indexed

About

Ana Montes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Ana Montes has authored 31 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Reproductive Medicine. Recurrent topics in Ana Montes's work include Ovarian cancer diagnosis and treatment (10 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers) and BRCA gene mutations in cancer (5 papers). Ana Montes is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers) and BRCA gene mutations in cancer (5 papers). Ana Montes collaborates with scholars based in United Kingdom, Spain and Italy. Ana Montes's co-authors include James Spicer, Debra H. Josephs, Sophia N. Karagiannis, Heather J. Bax, Sharmistha Ghosh, Giulia Pellizzari, Mano Nakamura, A. Winship, Chara Stavraka and Katie E. Lacy and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Cochrane Database of Systematic Reviews.

In The Last Decade

Ana Montes

31 papers receiving 232 citations

Peers

Ana Montes
Apostolos C Ziogas Greece
Marie-Mélanie Dauplat France
Ron Rye United Kingdom
Claudia Martins Canada
Songwei Feng China
Félix Blanc‐Durand France
Qi-Chun Cai China
Angela Burleigh Canada
Omer Devaja United Kingdom
Hanna Sallinen Finland
Apostolos C Ziogas Greece
Ana Montes
Citations per year, relative to Ana Montes Ana Montes (= 1×) peers Apostolos C Ziogas

Countries citing papers authored by Ana Montes

Since Specialization
Citations

This map shows the geographic impact of Ana Montes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Montes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Montes more than expected).

Fields of papers citing papers by Ana Montes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Montes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Montes. The network helps show where Ana Montes may publish in the future.

Co-authorship network of co-authors of Ana Montes

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Montes. A scholar is included among the top collaborators of Ana Montes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Montes. Ana Montes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banerjee, Susana, Anita Wolfer, Petronella B. Ottevanger, et al.. (2025). Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study. Clinical Cancer Research. 31(11). 2145–2153. 3 indexed citations
2.
Smith, Daniel, Andrea Billè, Akshay J. Patel, et al.. (2025). A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA). Clinical Lung Cancer. 26(3). e223–e231. 1 indexed citations
3.
Osborn, Gabriel, Chara Stavraka, Ahmad Sayasneh, et al.. (2021). Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clinical & Experimental Immunology. 209(1). 4–21. 15 indexed citations
4.
5.
Russell, Beth, Charlotte Moss, Kieran Palmer, et al.. (2021). COVID-19 infection in gastrointestinal (GI) cancer patients receiving systemic anticancer treatment (SACT) during the outbreak of the pandemic: The Guy's Cancer Centre experience.. Journal of Clinical Oncology. 39(3_suppl). 455–455. 1 indexed citations
6.
Nakamura, Mano, Gabriel Osborn, Roman Laddach, et al.. (2020). IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. Cancers. 12(11). 3376–3376. 16 indexed citations
7.
Bax, Heather J., Jitesh Chauhan, Chara Stavraka, et al.. (2020). Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. Cells. 9(7). 1631–1631. 31 indexed citations
8.
9.
Crawley, Danielle, Kerri Beckmann, Debra H. Josephs, et al.. (2020). Association of baseline characteristics and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (CPIs): Real-world evidence.. Journal of Clinical Oncology. 38(15_suppl). e21625–e21625. 1 indexed citations
10.
Jahn, Andreas, Carlos Río, Amanda Iglesias, et al.. (2020). Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis. 457–457. 1 indexed citations
11.
Roberts, Corran, Victoria Y. Strauss, Charlie Gourley, et al.. (2019). Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. British Journal of Cancer. 122(4). 483–490. 11 indexed citations
12.
Sharma, Rohini, Marianna Inglese, Suraiya Dubash, et al.. (2019). [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging. 47(5). 1239–1251. 14 indexed citations
13.
Nakamura, Mano, Heather J. Bax, Sam Sollie, et al.. (2019). Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. OncoImmunology. 8(6). e1593811–e1593811. 22 indexed citations
14.
Jahn, Andreas, Carlos Río, Ana Montes, et al.. (2019). Characterization of Mesenchymal Stem Cells obtained from human lungs with and without Idiopathic Pulmonary Fibrosis. PA1281–PA1281. 2 indexed citations
15.
El-Shakankery, Karim, Nadia Yousaf, Daniel Smith, et al.. (2017). Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer: A multi-centre retrospective analysis.. Journal of Clinical Oncology. 35(15_suppl). e20678–e20678. 1 indexed citations
16.
Bax, Heather J., Debra H. Josephs, Giulia Pellizzari, et al.. (2016). Therapeutic targets and new directions for antibodies developed for ovarian cancer. mAbs. 8(8). 1437–1455. 15 indexed citations
17.
Nicum, Shibani, Corran Roberts, Lucy Boyle, et al.. (2014). A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer. 14(1). 983–983. 10 indexed citations
18.
Montes, Ana, et al.. (2009). Nitrofurantoína y enfermedad pulmonar intersticial de rápida resolución. Archivos de Bronconeumología. 45(7). 352–355. 1 indexed citations
19.
Gore, Martin, Michelle Harrison, & Ana Montes. (2006). New drug therapies for advanced renal cell carcinoma. Expert Review of Anticancer Therapy. 7(1). 57–71. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Apostolos C Ziogas Breakdown of academic impact, for papers by Marie-Mélanie Dauplat Breakdown of academic impact, for papers by Ron Rye Breakdown of academic impact, for papers by Claudia Martins Breakdown of academic impact, for papers by Songwei Feng Breakdown of academic impact, for papers by Félix Blanc‐Durand Breakdown of academic impact, for papers by Qi-Chun Cai Breakdown of academic impact, for papers by Angela Burleigh Breakdown of academic impact, for papers by Omer Devaja Breakdown of academic impact, for papers by Hanna Sallinen
Rankless by CCL
2026